Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sage Therapeutic Com (SAGE)

Sage Therapeutic Com (SAGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Sage Therapeutic Com 215 FIRST STREET CAMBRIDGE MA 02142 USA

www.sagerx.com P: 617-299-8380 F: 617-299-8379

Description:

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 731,211
Enterprise Value, $K 658,891
Shares Outstanding, K 60,182
Annual Sales, $ 86,460 K
Annual Net Income, $ -541,490 K
Last Quarter Sales, $ 7,900 K
Last Quarter Net Income, $ -108,480 K
EBIT, $ -542,060 K
EBITDA, $ -547,010 K
60-Month Beta 0.90
% of Insider Shareholders 5.50%
% of Institutional Shareholders 99.22%
Float, K 56,872
% Float 94.50%
Short Volume Ratio 0.52

Growth:

1-Year Return -73.49%
3-Year Return -73.02%
5-Year Return -92.70%
5-Year Revenue Growth -4.22%
5-Year Earnings Growth -5.07%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.80 on 04/25/24
Next Earnings Date 08/05/24
Earnings Per Share ttm -7.84
EPS Growth vs. Prev Qtr -227.27%
EPS Growth vs. Prev Year 26.83%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

SAGE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -56.81%
Return-on-Assets % -51.01%
Profit Margin % -626.29%
Debt/Equity 0.00
Price/Sales 8.46
Price/Cash Flow N/A
Price/Book 1.01
Book Value/Share 11.73
Interest Coverage -0.76
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar